Checking your sign-in status…

Private workspace

Finance

Research, portfolio tools, and market analysis in one place.

Finance home
Back to US Equities

US Equities · Finance research note

LH — Labcorp

Research and analysis only
View analysis Browse US Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 10.95%
Profit Margins 6.66%
Return on Equity 11.05%
Return on Assets 5.31%
Free Float 0.08B
Dividend Yield 1.06%
Short Int % Utilisation 4.19%

2.2 Growth

Metric Value
Revenue Growth 5.8%
Free Cash Flow 1.14B
EBITDA 12.59 (Ratio)
Enterprise Value 28.36B
EV/Revenue 2.0
EV/EBITDA 12.59

Revenue growth of 5.8% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* 22.32%
Risk / Std Dev (Ann.)* 23.26%
1-Year Price Return* 18.90%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $318.13
52-Week Range $244.52 – $325.58
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in US$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont component Calculation FY2025 FY2024
Revenue Reported revenue $13.95B $13.01B
Net income Reported net income $876.50M $746.00M
Total assets Year-end reported balance $18.39B $18.38B
Shareholders’ equity Year-end reported balance $8.62B $8.05B
Net margin Net income ÷ revenue 6.28% 5.73%
Asset turnover Revenue ÷ total assets 0.7585x 0.7078x
Equity multiplier Total assets ÷ shareholders’ equity 2.1338x 2.2825x
ROE Net margin × asset turnover × equity multiplier 10.17% 9.26%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $13.95B
Prior annual revenue $13.01B
EBIT $1.33B
Tax rate 20.70%
NOPAT = EBIT × (1 − tax rate) $1.06B
Forecast start-growth basis 7.25%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $1.06B
Add: depreciation & amortisation $681.10M
Less: capital expenditure -$434.50M
Less/(add): working-capital cash-flow movement -$526.10M
Current unlevered FCFF $776.46M

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 7.25% $1.13B $730.46M -$465.99M -$564.23M $832.73M $801.26M
2 6.06% $1.20B $774.73M -$564.36M -$598.42M $813.07M $724.33M
3 4.87% $1.26B $812.49M -$665.40M -$627.59M $779.16M $642.65M
4 3.69% $1.31B $842.44M -$766.19M -$650.73M $731.63M $558.70M
5 2.50% $1.34B $863.51M -$863.51M -$666.99M $671.76M $474.94M

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 0.84
Cost of equity 9.35%
Pre-tax cost of debt 3.25%
WACC 8.01%
WACC validation within standard range

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $12.50B
Implied terminal EV / EBITDA 4.90x
Terminal value as % of enterprise value 72.64%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $3.20B
Present value of terminal value $8.50B
Indicated enterprise value $11.70B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $11.70B
Less: gross interest-bearing debt $6.53B
Add: cash and equivalents $532.30M
Add: affiliate investments $0.00
Less: minority interests $16.90M
Indicated common equity value $5.69B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 83,800,000.00
Share-count basis reported diluted weighted-average shares
Current market price $326.48
DCF indicative value per share $67.94
Indicative value vs. market price -79.19%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range pass
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 4/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:40:05.086799 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation input Value
Regional factor set US
Factor-return currency USD
Issuer-return basis USD adjusted total return
Estimation window 2025-08-19 to 2026-06-30
Aligned daily observations 217
Minimum observation requirement 120
Currency conversion for HK listings not required

Fama–French Three-Factor and Five-Factor Results

Diagnostic FF3 FF5
Annualised alpha -8.71% -0.77%
Adjusted R² 0.10 0.16
Annualised residual volatility 21.60% 20.71%
Factor loading (t-statistic) FF3 FF5
Market excess return (Mkt-RF) 0.27 (2.14) 0.48 (3.41)
Size (SMB) 0.58 (3.38) 0.40 (2.22)
Value (HML) 0.20 (1.33) -0.24 (-1.38)
Profitability (RMW) NM 0.10 (0.70)
Investment (CMA) NM 1.03 (4.00)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

us-equitystockequitylhhealth-carehealth-care-servicesnasdaq